Ikonisys Provides Global Business Update Against the Background of Recent Technology and Business Advancements
Paris, July 31, 2023 – 07:30 a.m. – Ikonisys SA (ISIN Code: FR00140048X2 / Ticker: ALIKO), a company specializing in the early and precise detection of cancer thanks to a unique and fully automated solution for medical diagnostic laboratories, presents an overview together and an update of its activity, following the latest successful developments since the beginning of the year.
In the first half of 2023, Ikonisys strengthened its R&D strategy, particularly in Circulating Tumor Cells (CTC) where the Company developed and implemented new dedicated software, and in AI, also thanks to the first results of the collaboration with the Polytechnic of Milan. Ikonisys will continue its efforts and have high expectations for its future CTC solutions, underpinned by its proven ability to turn R&D investments into concrete commercial advances, as demonstrated by the recent sales of the Ikoniscope20max. The installations in two important urology laboratories in the United States, and the validation of the first instrument installed, are the result of the technical and operational specificities of the Ikoniscope20max which have been efficiently developed by the R&D team thanks also to the strategic partnerships initiated in recent years.